Expanding reimbursement to the combined use of SGLT-2 inhibitors and DPP-4 inhibitors as treatment for diabetes has entered its final stages.

As the reimbursement will be carried out through voluntary price cuts by pharmaceutical companies as intended by the government, the process may proceed faster than when companies take the drug price negotiation track.

However, the fiscal burden on NHI finances, which remains the biggest issue, depends on the size of the voluntary price cuts that will be made by pharmaceutical companies. Therefore, agreeing on the amount of the price cuts may continue for several months.

Extending reimbursement to the combined use of three ingred